1. Oshima T et al. Epidemiology of Uninvestigated Dyspepsia and Functional Dyspepsia in Asia. Journal of General and Family Medicine.2015,16;4:235-241. https://doi.org/10.14442/jgfm.16.4_235
2. Francis P, Zavala SR. Functional Dyspepsia. In: StatPearls.Treasure island (FL):StatPearls Publishing;2022 Jan-.
3. Allescher HD, Abdel Aziz H. Mechanism of Action of STW5 in Functional Dyspepsia and IBS: the Origin of Multi-Target. Dig Dis 2017;35:18-24. DOI: 10,1159/000485456.
4. Talley NJ, Goodsall T, Potter M. Functional Dyspepsia. Aust Prescr 2017;40:209-13. https://doi.org/10.18773/austprescr.2017.066
5. Stanghellini V. Functional Dyspepsia and Irritable Bowel Syndrome: Beyond Rome IV. Dig Dis.2017;35(suppl 1):14-17. https:// doi.org /10.1159 /000 485408.
6. Wang YP, Herndon CC, Lu CL. Non-pharmacological Approach in the Management of Functional Dyspepsia. J Neurogastroenterol Motil. 2020 ;26(1):6-15. doi: 10.5056/jnm19005
7. Abdel-Aziz H, et al. Evaluating the Multitarget effects of combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast. Planta Med 2017;83:1130-1140.https://doi.org/10.1055/s-0043-116852.
8. Malfertheiner P. STW 5 (Iberogast) Therapy in gastrointestinal Functional Disorders. Dig Dis 2017;35:25-29. DOI: 10.1159/000485410.
9. Ottilinger B et al. STW 5 (Iberogast)- a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr. 2013;163:65-72. DOI: 10.1007/s10354-012-0169-x.
10. Gastin Force [Package Insert] Jakarta Indonesia. PT SOHO Industri Pharmasi Tbk;2022.
11. Perkumpulan Gastroenterologi Indonesia. Konsensus nasional Penatalaksanaan Irritable Bowel Syndrome (IBS) dan Dispepsia Fungsional di Indonesia Tahun 2021.
12. Brian E Lacy et al. American College of Gastroenterology Clinical Guideline: Management of Irritable Bowel Syndrome 2019. Am J Gastroenterol 2021;116:17-44. doi: 10.14309/ajg.0000000000001036
13. Eamonn MM Quigley et al. World Gastroenterology Organization Global Guidelines 2015. Irritable Bowel Syndrome: A global perspective. J Clin Gastroenterol.2016;50(9):704-13. DOI: 10.1097/MCG.0000000000000653
14. Vasant DH et al. British Society of Gastroenterology Guidelines 2021-Irritable Bowel Syndrome. Gut 2021;0:1-27.http://dx.doi.org/ 10.1136/gutjnl-2021-324598.
15. Lapina, T. and Trukhmanov, A., 2017. Herbal Preparation STW 5 for Functional Gastrointestinal Disorders: Clinical Experience in Everyday Practice. Digestive Diseases, 35(Suppl. 1), pp.30-35.
16. Raedsch R, Hanisch J, Bock P, et al. Wirksamkeit und Unbedenklichkeit des Phytopharmakons STW 5 versus Metoclopramid oral bei funktioneller Dyspepsie unter Praxisbedinungen. Z Gastroenterol. 2007;45(10):1041–8.
17. Zielińska S, Jezierska-Domaradzka A, Wójciak-Kosior M, Sowa I, Junka A, Matkowski AM. Greater Celandine's Ups and Downs-21 Centuries of Medicinal Uses of Chelidonium majus From the Viewpoint of Today's Pharmacology. Front Pharmacol. 2018 Apr 11;9:299. doi: 10.3389/fphar.2018.00299. PMID: 29713277; PMCID: PMC5912214.
18. National Prescribing Service (NPS) Australia. Iberogast Product Information. NPS, February 2020.
19. Kim, Y., Kim, J., Ha, N., Kim, J. and Ryu, H. Herbal Therapies in Functional Gastrointestinal Disorders: A Narrative Review and Clinical Implication. Frontiers in Psychiatry 2020, 11.
20. Black, C., Houghton, L. and Ford, A., 2018. Insights into the evaluation and management of dyspepsia: recent developments and new guidelines. Therapeutic Advances in Gastroenterology, 11, p.175628481880559.
21. Pilichiewicz AN, Horowitz M, Russo A, Maddox AF, Jones KL, Schemann M, Holtmann G, Feinle-Bisset C. Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol. 2007 Jun;102(6):1276-83. doi: 10.1111/j.1572-0241.2007.01142.x. Epub 2007 Mar 22. PMID: 17378904.
22. Marx L, Grundmann D, Schreiber D, et al. Intestinal inflammation and motility: How does STW 5 influence this? Zeitschrift für Phytotherapie. 2016;37(S 01). doi:10.1055/s-0036-1584481
23. Rösch W, Vinson B, Sassin I. A randomized clinical trial comparing the efficacy of a herbal preparation STW; with the prokinetic drug; cisapride in patients with dysmotility type of functional dyspepsia. Zeitschrift für Gastroenterologie. 2002;40(6):401-408. doi:10.1055/s-2002-32130
24. Harer KN, Hasler WL. Functional Dyspepsia: A Review of the Symptoms, Evaluation, and Treatment Options. Gastroenterology & Hepatology. 2020;6(2):66-74.
25. von Arnim, U., Peitz, U., Vinson, B., Gundermann, K., & Malfertheiner, P. STW 5, a Phytopharmacon for Patients With Functional Dyspepsia: Results of a Multicenter, Placebo-Controlled Double-Blind Study. The American Journal Of Gastroenterology, 2007. doi: 10.1111/j.1572-0241.2006.01183.x